Liaoning Chengda BiotechnologyLtd Full Year 2023 Earnings: EPS: CN¥1.12 (vs CN¥1.71 in FY 2022)

Liaoning Chengda BiotechnologyLtd (SHSE:688739) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥1.75b (down 3.6% from FY 2022).
• Net income: CN¥465.9m (down 35% from FY 2022).
• Profit margin: 27% (down from 39% in FY 2022). The decrease in margin was primarily driven by higher expenses.
• EPS: CN¥1.12 (down from CN¥1.71 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Liaoning Chengda BiotechnologyLtd Earnings Insights

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Liaoning Chengda BiotechnologyLtd (1 doesn't sit too well with us!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.